-
Cara Therapeutics Initiates Phase I Study With Oral Formulation Of Novel Peripherally-Acting Kappa Opioid Agonist
11/23/2011
Cara Therapeutics, Inc. today announced the initiation of a first-in-man Phase I clinical trial of an oral formulation of its peptide-based, kappa opioid agonist, CR845, in healthy volunteers.
-
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use In 45% Of Patients With Serious Form Of Childhood Arthritis
11/8/2011
Novartis announced recently new pivotal Phase III data showing 45% of children with active systemic juvenile idiopathic arthritis (SJIA) were able to substantially reduce their use of oral corticosteroids (often described as steroids) within 28 weeks of commencing treatment with ACZ885 (canakinumab) (p<0.0001).
-
Novartis Achieves Strong Third Quarter Financial Performance And Pipeline Progress
10/28/2011
Novartis is announcing recently additional cost reduction activity, which will be executed over three to five years. Elements of the activity to include: reallocation of production within the Novartis network resulting in closure of two sites in Switzerland and one in Italy; restructuring the development organization largely in Switzerland and the US and relocating some research activities from Switzerland to the US.
-
Merck Announces Presentation Of Phase III Investigational Studies Evaluating DULERA® (Mometasone Furoate And Formoterol Fumarate Dihydrate) Inhalation Aerosol in Chronic Obstructive Pulmonary Disease (COPD)
10/27/2011
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from two 26-week investigational Phase III clinical studies evaluating the efficacy and safety of two dose strengths of DULERA® (mometasone furoate and formoterol fumarate dihydrate) in adults 40 years and older with moderate to very severe chronic obstructive pulmonary disease (COPD).
-
Approval Of US Pilot Clinical Trial To Evaluate AclarusDx™, The Exonhit Investigational Test For Alzheimer's Disease Diagnosis
10/27/2011
Exonhit (Paris:ALEHT) announced today the Institutional Review Board (IRB) approval of Exonhit sponsored pilot clinical trial aimed at evaluating the performance of AclarusDx™, a blood based investigational diagnostic test, in US-based patients suffering from memory impairment and newly referred to a reference Memory Center for Alzheimer’s Disease (AD) diagnostic workup. This study will be conducted by the Cleveland Clinic Lou Ruvo Center for Brain Health.
-
Phase II Study Showed Ocrelizumab Maintained Significant Reduction In Disease Activity For Multiple Sclerosis Patients For Almost Two Years
10/19/2011
Genentech, a member of the Roche Group, recently announced 96-week results1 from a Phase II study of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS), the most common clinical form2 of the disease.
-
Novartis Drug Gilenya (Fingolimod) Has More Than 20,000 Patient-Years Of Exposure And Shows Up To 71% Reduction In Annualized Relapse Rates In MS Patients With Highly Active Disease
10/18/2011
Novartis will showcase data from 13 abstracts on fingolimod (Gilenya), at the 5th Joint Triennial Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) and Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) taking place from 19-22 October in Amsterdam.
-
Roche NimbleGen Announces New Pre-Capture Multiplexing For Target Enrichment Technology In Sequencing
10/12/2011
With the decreasing cost and increasing throughput of sequencing, researchers require a high-performance, cost-effective sample preparation pipeline for targeted sequencing.
-
Roche Licenses Nanopore Sequencing Technologies From Arizona State University And Columbia University For Rapid, Affordable DNA Sequencing
10/12/2011
Roche and Arizona Technology Enterprises (AzTE) announced recently an agreement to license several technologies developed by Dr. Stuart Lindsay at the Biodesign Institute at Arizona State University and Dr. Colin Nuckolls of the Columbia University Nanoscience Center for the development of a revolutionary DNA sequencing system.
-
Santaris Pharma A/S To Report New Clinical Data From Miravirsen Phase 2a Study To Treat Hepatitis C In Late-Breaking Oral Presentation At The AASLD 2011 Annual Meeting
10/4/2011
Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA and mRNA-targeted therapies, today announced the Company will report new clinical data results from the miravirsen Phase 2a proof-of-concept study to treat patients infected with the Hepatitis C virus (HCV) in a late-breaking oral presentation session at the American Association for the Study of Liver Diseases (AASLD) 2011 annual meeting.
